Media stories about Midatech Pharma (NASDAQ:MTP) have trended somewhat negative recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Midatech Pharma earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.2798389342642 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Midatech Pharma (NASDAQ MTP) traded down $0.11 during midday trading on Friday, hitting $1.36. 4,629 shares of the stock were exchanged, compared to its average volume of 8,822. Midatech Pharma has a 1 year low of $1.00 and a 1 year high of $3.65. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.49 and a current ratio of 1.62.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at

Midatech Pharma Company Profile

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Insider Buying and Selling by Quarter for Midatech Pharma (NASDAQ:MTP)

Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.